|
|
||||||
|
Recognising the prominent role of biosimilar medicines in delivering access to life-changing biological therapies, the ongoing dialogue on cancer and other non-communicable diseases is pointing towards greater value for healthcare systems, enabling progress towards integrated care for patients. Throughout the conference, debate and exchanges, as well as the presentation of examples and current practices, will foster ideas and data sharing. The aim of this event is to multiply perspectives on existing challenges and future opportunities for biosimilar medicines policy to drive efficiency and contribute to the transformation of healthcare systems, and to inform the revision of the Pharmaceutical legislation. |
||||||
|
Join us and have your say! As a participant in this event, you will:
We look forward to welcoming you to our event in Brussels! In the meantime, please take a look at the April BIOS22 webinar "Biosimilar medicines: Changing patient pathways, Changing outcomes" during which we discussed biosimilar medicines value for healthcare.
|
|
CONTACT |



